Tin tức & Cập nhật
Xem bài viết Da liễu
Xem

Personalized mRNA cancer vaccine + pembrolizumab hits targets in phase III melanoma trial
In the large phase III INTerpath-001 study evaluating individuals with resected stage IIB–IV melanoma, recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) improved when the mRNA-based individualized neoantigen therapy intismeran autogene was added to pembrolizumab compared with pembrolizumab alone.

Tranquillo data support ritlecitinib for NSV
In two pivotal phase III Tranquillo studies, individuals with nonsegmental vitiligo (NSV) achieved significant and clinically meaningful improvements in facial and total body repigmentation after 52 weeks of treatment with oral ritlecitinib.

ARCADIA LTE supports long-term efficacy, safety of nemolizumab for AD
The open-label long-term extension (LTE) of the ARCADIA trial demonstrates the safety and efficacy of nemolizumab for up to 152 weeks in adults and adolescents with moderate-to-severe atopic dermatitis (AD).





